Soligenix Aktie [WKN DE: A2AS7Q / ISIN: US8342233074]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Soligenix Inc Registered Shs (Old)

03.10.24		Soligenix, Sterling Pharma Partner To Develop Production Technology For Synthetic Hypericin (RTTNews)
25.06.24		Soligenix Rises In Pre-Market On Positive Results From Study Of HyBryte Vs. Valchlor In CTCL (RTTNews)
25.06.24		Soligenix Reports Positive Results From Study Of HyBryte Vs. Valchlor In Cutaneous T-cell Lymphoma (RTTNews)
31.05.24		Soligenix Announces 1-for-16 Reverse Stock Split (RTTNews)
11.04.24		Soligenix's SuVax Granted FDA Orphan Drug Designation For Prevention Of Sudan Ebolavirus Infection (RTTNews)
04.01.24		Soligenix Reports Positive Preliminary Results From Phase 2a Study Of SGX302 In Psoriasis (RTTNews)
02.01.24		Soligenix Reports Preclinical Efficacy Of Bivalent Vaccine Against Two Viruses (RTTNews)
02.01.24		Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses (PR Newswire)
01.12.23		"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery (PR Newswire)
30.11.23		FDA Clears Phase 2a Study Of SGX945 To Treat Aphthous Ulcers In Behcet's Disease (RTTNews)
30.11.23		Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease (PR Newswire)
17.11.23		Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire)
13.11.23		Soligenix Q3 Loss Narrows (RTTNews)
13.11.23		Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results (PR Newswire)
20.10.23		Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire)
16.10.23		Soligenix to Present at The ThinkEquity Conference (PR Newswire)
25.09.23		Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures (PR Newswire)
22.09.23		Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders (PR Newswire)
21.08.23		Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results (PR Newswire)
10.08.23		HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment (PR Newswire)
11.07.23		Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis (PR Newswire)
16.05.23		Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis (PR Newswire)
15.05.23		Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results (PR Newswire)
11.05.23		Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
09.05.23		Soligenix Announces Closing of $8.5 Million Public Offering (PR Newswire)
05.05.23		Soligenix Announces Pricing of $8.5 Million Public Offering (PR Newswire)
04.05.23		Soligenix Announces Positive Results From Study Of HyBryte In CTCL Treatment; Stock Surges (RTTNews)
04.05.23		Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
01.05.23		Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease (PR Newswire)
24.04.23		Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
14.04.23		Soligenix Provides Regulatory Update on HyBryte™ (PR Newswire)
05.04.23		Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302 (PR Newswire)
03.04.23		Soligenix Says FDA Grants Type A Meeting Regarding New Drug Application For HyBryte (RTTNews)
03.04.23		Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
31.03.23		Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results (PR Newswire)
09.03.23		Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
14.02.23		Soligenix Receives Refusal To File Letter From FDA For HyBryte NDA (RTTNews)
14.02.23		Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
09.02.23		Soligenix Announces Reverse Stock Split (PR Newswire)
19.01.23		Soligenix Invited to Present at the Virtual Investor Summit Event (PR Newswire)
23.12.22		Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock (PR Newswire)
20.12.22		Soligenix: Positive Correlates Of Protection With RiVax In NHP Survival After Ricin Challenge (RTTNews)
20.12.22		Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge (PR Newswire)
19.12.22		Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis (PR Newswire)
15.12.22		Soligenix Submits NDA For HyBryte (RTTNews)
15.12.22		Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma (PR Newswire)
15.11.22		Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program (PR Newswire)
10.11.22		Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results (PR Newswire)
27.10.22		Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses (PR Newswire)
25.10.22		Soligenix Announces Formation of Psoriasis Medical Advisory Board (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

XRP mit Rekordrally: Ripple-CEO glaubt an US-Krypto-Boom unter Trump

Pierer-Aktie letztlich zweistellig höher: KTM ist insolvent - Antrag auf Sanierung in Eigenverwaltung

Ripple steigt deutlich: Neues ATH noch in 2024?

VW-Aktie unter Druck: Flächendeckender Streik bei Volkswagen - Tausende Jobs in Österreich abhänging

KTM-Insolvenz: Betriebsversammlungen gestartet

Ripple im Höhenflug: XRP steigt um 30 Prozent und erreicht Top-3 der Kryptowährungen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	04.12.2024 20:25
Kaufwert:	EUR
	Hinzufügen Speichern